Related Experiment Videos
New approaches to the treatment of angina pectoris
Insights
Percutaneous coronary intervention (PCI) offers a safe and effective treatment for selected patients with coronary artery disease, relieving symptoms in half. Further research is needed to compare PCI, coronary artery bypass grafting (CABG), and drug regimens.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiovascular Surgery
Background:
- Coronary artery disease (CAD) patient management requires individualized treatment.
- Treatment decisions depend on symptom severity, lesion extent, and left ventricular function.
Purpose of the Study:
- To evaluate the role of percutaneous transluminal coronary angioplasty (PTCA) in managing ischemic heart disease.
- To highlight the need for comparative studies of PTCA, coronary artery bypass grafting (CABG), and medical management.
Main Methods:
- Review of current treatment strategies for coronary artery disease.
- Discussion of patient selection criteria for PTCA and surgery.
- Identification of the need for prospective randomized clinical trials.
Main Results:
- PTCA is safe and effective for patients with discrete proximal lesions causing medically refractory angina.
- PTCA relieves ischemic symptoms in approximately 50% of eligible patients.
- Recurrence of symptoms occurs in one-third, often resolved with repeat PTCA; infarction and death rates are comparable to CABG.
Conclusions:
- PTCA is a viable option for specific CAD patient subsets.
- A definitive randomized trial comparing PTCA, CABG, and drug therapy is essential for optimal ischemic heart disease treatment.
Abstract:
Patients with coronary artery disease represent a highly heterogeneous group and require individualized treatment based on severity of symptoms, extent and distribution of coronary artery lesions, and left ventricular function. Patients with left main coronary artery disease or triple-vessel disease and left ventricular dysfunction should be referred for surgery, as should patients satisfying the Veterans Administration high-risk group criteria, as well as those patients with intractable symptoms unsuitable for PTCA. Patients in whom discrete proximal lesions in a single coronary artery have caused recent onset of medically refractory angina should be considered for PTCA. In these patients, PTCA has been proven to be both a safe and effective technique. The procedure will relieve the signs and symptoms of myocardial ischemia in half of these patients. One third of this group will have a recurrence of their symptoms but will return to an asymptomatic state for a prolonged period following a second PTCA procedure. The rate of infarction and death compares favorably with that seen with CABG surgery. What are the relative merits of PTCA vs. CABG surgery or drug regimens in the treatment of ischemic heart disease? To answer this critical question, a well-defined prospective randomized clinical trial is needed. The results of such a trial may usher in a new era in the treatment of ischemic heart disease.